Blogs about Biotechnology, Pharmaceutical and Healthcare

14:53 EDT 24th October 2014 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 62,000+

Friday 24th October 2014

European Backing For AstraZeneca’s Olaparib Bolsters Barriers To Pfizer

Europe’s top medicines advisory panel, the CHMP, also recommended for approval Clinuvel’s Scenesse for severe intolerance to sunlight, Pfizer’s new combination menopausal symptom therapy Duavive, and Baxter’s new hemophilia B therapy Rixubis.

Video: Wuxi’s Mission Critical – Fostering Innovation by Servicing Biopharma

It might act like a biopharmaceutical firm, but Wuxi Apptec’s Richard M. Soll, senior VP, International Discovery Service Unit, told BioWorld it’s still a CRO. He also discussed Wuxi’s role in helping to obtain the first U.S. FDA approval of a biologic product made by a Chinese company. Enjoyed this article? Subscribe to Life Sciences […] The post Video: Wuxi’s Missio...

East Coast Biotech Roundup: PureTech, Celgene, Unum, Biogen & More

Deal flow is in full swing on the East Coast. At least three life sciences startups launched out of Boston and New York this week, with a few other firms filling up their bank accounts with either new funding rounds or partnership deals. Those storie...

Current and Emerging Approaches to Acquired Resistance for ALK/ROS1

_kmq.push(["trackClickOnOutboundLink","wpa2a_4","Article link clicked",{"Title":"","Page":"Current and Emerging Approaches to Acquired Resistance for ALK\/ROS1"}]);Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called “next generation” ALK/ROS1 inhibitors, both those commercially available and those still in development...

Is Merck The Right Dividend Stock To Have In A Portfolio?

LabCorp: Double-Digit Total Returns In Sight For The Foreseeable Future

ImmunoGen's (IMGN) CEO Daniel Junius on Q1 2015 Results - Earnings Call Transcript

Jim Cramer: Celgene, Gilead Leading Biotech Charge Higher

Click to view a price quote on CELG.

Varian: Earnings Miss, Mild Reduction In FVE, But Shares Still Undervalued

Edwards Lifesciences (EW) Stock Is Up Double Digits Today After Raising Full Year Forecast

Click to view a price quote on EW.

Cannabis Can Harm Your (Financial) Health

Group Jean Coutu: An Update

The more we know about rare diseases, the more likely we are to find safe and effective treatments

By: Janet Woodcock, M.D. You may be inclined to think that rare diseases affect only a tiny fraction of the more than 320 million people in our country. That’s true about a single rare disease. But there are about 7,000 … Continue reading →

LifePoint Hospitals (LPNT) Q3 2014 Results - Earnings Call Webcast

Magellan Health Services (MGLN) Q3 2014 Results - Earnings Call Webcast

Pfizer Yielding 8.7%? It Could Happen More Easily Than You Think

Assimilating independent physician practices: Is resistance futile?

Fans of Star Trek: The Next Generation will recall that the most disturbing aliens encountered by the Federation were the Borg, a part-cyber, part human collective race that functioned as an integrated and cyber-connected whole that existed only for the good of the collective, rather than as distinct individuals with their own thoughts and personalities — much […]

Biotech Breakout: Technical Analysis And Major News

Trinity Biotech's (TRIB) CEO Ronan O'Caoimh on Q3 2014 Results - Earnings Call Transcript

ImmunoGen (IMGN) Q3 2014 Results - Earnings Call Webcast

ModernGraham Quarterly Valuation Of Eli Lilly & Co.

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

Click to view a price quote on RMTI.

Quit smoking: It takes a community to spread the word

You never know when something special is going to happen, as in one of those times when you just wish you had a camera rolling to capture a moment, a comment, a statement about the way the world is — and the way the world could be. This past weekend my wife and I were […]

Francis Collins Knows Why We Don't Have An Ebola Vaccine

NIH Director Francis Collins has been saying that if only the agency's budget hadn't been cut, that we would already have an Ebola vaccine. He tried this line out during recent Congressional testimony, and apparently liked it enough that he expanded ...

The lack of joy at the doctor’s office, and a reason why

Ruth was problematic.  Well into her seventies, her body may have dulled but her tongue was sharper than ever.  And she used it to lash me with complaint after complaint.  If it wasn’t her knees, it was her ankles.  If it wasn’t her ankles, it was her hips.  I battled the impossible month after month, […]

Search BioPortfolio: